Therapeutic cytokine stimulation of thrombocytopoiesis

Transfusion Science

Volumn 19, Issue 2, 1998, Pages 149-162

  Harker, Laurence A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 3; INTERLEUKIN 6; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT CYTOKINE; RECOMBINANT THROMBOPOIETIN; STEM CELL FACTOR; THROMBOPOIETIN;

BABOON; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CAROTID ARTERY THROMBOSIS; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MOLECULAR CLONING; NONHUMAN; RABBIT; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; THROMBOGENESIS;

EID: 0345770235     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(98)00025-3     Document Type: Article

References (92)

1. Souyri M., Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F: A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990; 63:1137-1147.
2. Vigon I, Mornon J-P., Cocault L: Molecular cloning and characterization of mpl, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992; 89:5640-5644.
3. Methia N, Louache F, Vainchenker W, Wendling F: Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82:1395-1401.
4. deSauvage FJ, Hass PE, Spencer SD, et al.: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-mpl ligand. Nature 1994; 369:533-538.
5. Lok S, Kaushansky K, Holly RD, et al.: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369:565-568.
6. Bartley TD, Bogenberger J, Hunt P, et al.: Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor mpl. Cell 1994; 77:1117-1124.
7. Hoffman R: Human hematopoietic stem cells: potential use as tumor-free autografts after high-dose myeloablative cancer therapy. Am J Med Sci 1995; 309:254-266.
8. Greenberg SM, Kuter DJ, Rosenberg RD: In vitro stimulation of megakaryocyte maturation by megakaryocyte factor. J Biol Chem 1987; 262:3269-3277.
9. Paulus, J. M.: Platelet kinetics: Radioisotopic, Cytological, Mathematical and Clinical Aspects. Amsterdam, North-Holland, 1971, pp. 1-360.
10. Tomer A, Harker LA, Burstein SA: Flow cytometric analysis of normal human megakaryocytes. Blood 1988; 71:1244-1252.
11. Choi ES, Hokom M, Bartley T, et al.: Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-mpl, produces functional human platelets in vitro. Stem Cells 1995, 13:317-322.
12. Kaushansky K, Lok S, Holly RD, et al.: Promotion of megakaryocyte progenitor expansion and differentiation by the c-mpl ligand thrombopoietin. Nature 1994; 369:568-571.
13. Wendling F, Maraskovsky E, Debili N, et al.: c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369:571-574.
14. Kuter DJ, Beeler DL, Rosenberg RD: The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91:11104-11108.
15. Kaushansky K: Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86:419-431.
16. Kato T, Ogami K, Shimada Y, et al.: Purification and characterization of thrombopoietin. J Biochem 1995, 118:229-236.
17. Broudy VC, Lin NL, Kaushansky K: Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and IL-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995; 85:1719-1726.
18. Ku H, Yonemura Y, Kaushansky K, Ogawa M: Thrombopoietin, the ligand for the Mpl receptor, synergy with steel factor and other early-acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 1996; 87:4544-4551.
19. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M: Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood 1995; 88:429-436.
20. Odell TT, McDonald TP, Detwiler TC: Stimulation of platelet production by serum of platelet-depleted rats. Proc Soc Exp Biol Med 1961; 108:428-431.
21. Harker LA: Kinetics of thrombopoiesis. J Clin Invest 1968; 47:458-465.
22. Evatt BL, Shreiner DR, Levin J: Thrombopoietic activity of fractions of rabbit plasma: studies in rabbits and mice. J Lab Clin Med 1974; 83:364-371.
23. Mazur E, South K: Human megakaryocyte colony-stimulating factor in serafrom aplastic anaemia dogs: partial purification, characterization and determination of hematopoietic cell lineage specificity. Exp Hematol 1985; 13:1164-1172.
24. Tayrien G, Rosenberg RD: Purification and properties of a megakaryocyte stimulatory factor present both in the serum-free conditioned medium of human embryonic kidney cells and in thrombocytopenic plasma. J Biol Chem 1987; 262:3262-3267.
25. Nichol JL, Hokom MM, Hornkohl A, et al.: Megakaryocyte growth and develop ment factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995; 95:2973-2978.
26. Stoffel R, Wiestner A, Skoda RC: Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level arid for a direct regulatory role of platelets. Blood 1996; 87:567-573.
27. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW: Thrombocytopenia in c-mpl-deflcient mice. Science 1994; 265:1445-1447.
28. de Sauvage FJ, Luoh S-M, Carver-Moore K, Ryan A, Dowd M, Eaton DL, Moore MW: Deficiencies in early and late stages of megakaryocytopoiesis in TPO-KO mice. Blood 1995; 86:255a (abstract).
29. deSauvage FJ, Carver-Moore K, Luoh SM: Physiologic regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996; 183:651-656.
30. McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K: Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995; 86:3668-3675.
31. Sungaran R, Markovic B, Chong BH: Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow and spleen using in situ hybridization. Blood 1997; 89:101-107.
32. Kuter DJ, Rosenberg RD: Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood 1994; 84:1464-1472.
33. Harker LA, Marzec UM, Hunt P, et al.: Dose-response effects of pegylated human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet production and function in nonhuman primates. Blood 1996; 88:511-521.
34. Harker LA, Marzec UM, Sundell-Ranby B, Kelly AB, Nichol J, Cheung E, Stead RB: Recombinant human thrombopoietin in nonhuman primates: dose-response effects on pharmacokinetics, megakaryocytopoiesis, platelet production, function and TPO-receptor density Blood 1998 (in press).
35. Harker LA, Hunt P, Marzec UM, et al.: Regulation of platelet production and function by megakaryocyte growth and development factor (MGDF) in nonhuman primates. Blood 1996; 87:1833-1844.
36. Harker LA, Toombs CF, Stead RB: In vivo, dose-response effects of mpl ligands on platelet production and function, in Kuter DJ, Hunt P, Sheridan W, ZuckerFranklin D (eds): Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology, Totowa, NJ, Humana Press, 1997, p. 301.
37. Harker LA, Finch CA: Thrombokinetics in man. J Clin Invest 1969; 48:963-974.
38. Slichter SJ, Harker LA: Thrombocytopenia mechanisms and management of defects in platelet production. Clin Haematol 1978; 7:523-539.
39. Marsh JC, Gibson FM, Prue RL, et al.: Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol 1996; 95:605-610.
40. Nichol JL: Serum levels of thrombopoietin in health and disease, in Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D (eds). Thrombopoiesis and Thrombopoietins Totowa, NJ, Humana Press, 1997, p. 359.
41. Vadhan-Raj S, Murray LJ, Bueso-Ramos C: Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in cancer patients. Ann Intern Med 1997; 126:673-681.
42. Toombs CF, Young CH, Glaspy JA, Varnum BC: Recombinant human megakaryocyte growth and development factor (MGDF) moderately enhances ex vivo platelet aggregation by a receptor dependent mechanism. Thromb Res 1995; 80:23-33.
43. Drachman JG, Griffin JD, Kaushansky K: The c-mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc and c-mpl. J Biol Chem 1995; 270:4979-4982.
44. Miyakawa Y, Oda A, Druker BJ, et al.: Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 1996; 87:439-446.
45. Grabarek J, Groopman JE, Lyles YR, et al.: Human kit ligand (stem cell factor) modulates platelet activation in vitro., J Biol Chem 1994; 269:21718-21724.
46. Shimoda K, Okamura S, Harada N, Kondo S, Okamura T, Niho Y: Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest 1993; 91:1310-1313.
47. Decoster G, Rich W, Brown SL: Safety profile of filgrastim (r-metHuG-CSF), in Morstyn G, Dexter TM (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice, New York. Marcel-Dekker, Inc. 1994, p. 267.
48. Sheridan WP, McNiece I: Stem cell factor, in Armitage JO, Antman KH (eds): High-Dose Cancer Therapy. Pharmacology, Hematopoietins, Stem Cells. Baltimore, Williams & Wilkins, 1995, p. 429.
49. Toombs CF, Lott FD, Nelson AG, Stead RB: Megakaryocyte growth and development factor (MGDF) promotes platelet production in vivo without affecting in vivo thrombosis. Blood 1995; 86:369a (abstract).
50. Harker LA, Hanson SR: Platelet factors predisposing to arterial thrombosis, in Meade TW (ed): Bailliere's Clinical Haematology. London, Bailliere Tindall, 1994, p. 499.
51. Harker LA, Slichter SJ: The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972; 287:155-159.
52. Shulman NR, Watkins SP, Itscoitz SB, Students AB: Evidence that the spleen retains the youngest and hemostatically most effective platelets. Trans Assoc Am Physician 1968; 81:302-313.
53. Blajchman MA, Senyi AF, Hirsh J, Genton E, George JN: Hemostatic function, survival, and membrane glycoprotein changes in young versus old rabbit platelets. J Clin Invest 1981; 68:1289-1294.
54. Thiagaraian P, Tait JF: Binding of annexin VJplacental anticoagulant protein I to platelets. J Biol Chem 1990; 265:17420-17423.
55. Dachary-Prigent J, Freyssinet J-M., Pasquet J-M, Carron J-C., Nurden AT: Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood 1993; 81:2554-2565.
56. Cole JL, Marzec UM, Gunthel CJ, et al.: Ineffective platelet production in thrombocytopenic HIV-infected patients. Blood 1998; 91:3239-3246.
57. Fielder PJ, Hass P, Nagel M, et al.: Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89:2782-2788.
58. Gordon MS, Hoffman R: Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood 1992; 80:302-307.
59. Cwirla SE, Balasubramanian P, Duffin DJ: Peptide agonist of the thrombapoietin receptor as potent as the natural hormone. Science 1997; 276:1696-1699.
60. Folts JD: An in vivo model of experimental arterial stenosis, intimal damage and periodic thrombosis. Circulation 1991; 83:3-14.
61. Golino P, Ambrosio G, Pascucci I, Ragni M, Russolillo E, Chiariello M: Experimental carotid stenosis and endothelial injury in the rabbit: an in vivo model to study intravascular platelet aggregation. Thromb Haemost 1992; 67:302-305.
62. Harker LA, Kelly AB, Hanson SR: Experimental arterial thrombosis in non-human primates. Circulation 1991; 83 (Suppl IV)):IV-41.
63. Kelly AB, Marzec UM, Krupski W, et al. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77:1006-1012.
64. Folts JD, Rowe GG: Cyclical reductions in coronary blood flow in coronary arteries with fixed partial obstruction and their inhibition with aspirin. Fed Proc 1974; 33:413-415.
65. Demrow HS, Slane PR, Folts JD: Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 1995; 91:1182-1188.
66. Ramjit DR, Lynch JJ, Jr., Sitko GR, et al.: Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis. J Pharmacol Exp Therap 1993; 266:1501-1511.
67. Olbrich C, Aepfelbacher M, Siess W: Epinephrine potentiates calcium mobilization and activation of proteins kinases in platelets stimulated by ADP through a mechanism unrelated to phospholipase C. Cell Signal 1989; 1:483-492.
68. Ulich TR, Castillo J, Yin S, et al.: Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86:971-976.
69. Farese AM, Hunt P, Grab LB, MacVittle TJ: Combined administration of recombinant human megakaryocyte growth and development factor, and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest 1996; 97:1-7.
70. Ulich TR, del Catillio J, Senaldi G: Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996; 87:5006-5015.
71. Grossmann A, Lenox J, Ren HP: Thrombopoietin accelerates platelet, red blood cells and neutrophil recovery in myelosuppressed mice. Exp Hematol 1996; 24:1238-1246.
72. Grossmann A, Lenox J, Deisher T: Synergistic effects of thrombopoietin and G-CSF on neutrophil recovery in myelosuppressed mice. Blood 1996; 88:3363-3370.
73. Akahori H, Shibuya K, Ozai M: Effects of pegylated recombinant megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice. Stem Cells 1996; 14:678-689.
74. Akahori H, Shilbuya K, Obuchi W: Affect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Haematol 1996; 94:722-728.
75. Andrews RG, Winkler A, Myerson D: Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons. Stem Cells 1996; 14:661-667.
76. Harker LA, Marzec UM, Kelly AB, et al.: Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human in megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Blood 1997; 89:155-165.
77. Neelis KJ, Qingliang L, Thomas GR, Cohen BL, Eaton DL, Wagemaker G: Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion. Blood 1997; 90:58-63.
78. Kaushansky K, Broudy VC, Grossmann A: Thrombopoietin expands erythroid progenitors, increases red cell production, arid enhances erythroid recovery after myelosuppressive therapy. J Clin Invest 1995; 96:1683-1687.
79. Kobayashi M, Laver JH, Kato T: Recombinant human thrombopoietin (mpl ligand) enhances proliferation of erythroid progenitors. Blood 1995; 86:2494-2499.
80. Sitnicka E, Lin N, Priestley GV: The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996; 87:4998-5005.
81. Molineux G, Hartley CA, McElroy P, McCrea C, McNiece IK: Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation. Blood 1996; 88:1509-1514.
82. Kabaya K, Shibuya K, Torii Y: Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice. Bone Marrow Transplant 1996; 18:1035-1041.
83. Fibbe WE, Heemskerk DPM, Laterveer L, et al.: Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 1995; 86:3308-3313.
84. O'Malley CJ, Rasko JEJ, Basser RL, et al.: Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996; 88:3288-3298.
85. Fanucchi M, Glaspy J, Crawford J, et al.: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development, factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336:404-409.
86. Basser RL, Rasko JEJ, Clarke K, et al.: Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348:1279-1281.
87. Basser RL Rasko JEJ, Clarke K, et al.: Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89:3118-3128.
88. Beveridge R, Schuster M, Waller E, et al.: Randomized, double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-Rhumgdf) in breast cancer patients (Pts) following autologous bone marrow transplantation (ABMT). Blood 1997; 90:580a (abstract).
89. Kuter D, McCullough J, Romo J, et al.: Treatment of platelet (PLT) donors with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increases circulating PLT counts (CTS) and PLT apheresis yields and increases platelet increments in recipients of PLT transfusions. Blood 1997; 90:579a (abstract).
90. George JN, El-Harake MA, Aster RH: Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms, in Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds): Hematology. New York, McGraw-Hill, Inc. 1995, p. 1315.
91. Harker LA Marzec UM, Novembre F, et al.: Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor. Blood 1998; 91:4427-4433.
92. Tepler I, Elias L, Smith W: A randomized placebo-controlled trial of recombinant IL-11 in cancer patients with severe thrombocytopenia due to cancer. Blood 1996; 87:3607-3614.